RxDoctor Payments Data

Mary Evers, DO

Dermatology · Georgetown, TXNPI 1053533026

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 68 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$144
  • Regeneron Healthcare Solutions, Inc.$108
  • Sanofi$106
  • UCB, Inc.$105
  • Pfizer$102
  • Johnson & Johnson$84
  • plus $734 from 15 others

What the payments were for

  • Food & beverage$1,31395%
  • Education$705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 30th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$703,203
Medicare patients
1,495
Services billed
13,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$70,544
Dutasteride132$6,479
Azelaic Acid51$5,813
Tavaborole38$5,491
Clobetasol Propionate88$3,830
Fluocinonide119$3,313
Metronidazole43$3,271
Triamcinolone Acetonide223$2,237
Mupirocin279$2,175
Mycophenolate Mofetil29$2,041
Clindamycin Phosphate53$1,857
Ketoconazole134$1,853
Doxycycline Hyclate75$1,783
Econazole Nitrate45$1,688
Fluorouracil29$1,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$144$70,54413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →